Combination pharmacotherapy in unipolar depression

Expert Review of Neurotherapeutics

Volumn 6, Issue 7, 2006, Pages 1049-1060

  Ng, Felicity ^a   Dodd, Seetal ^a   Berk, Michael ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antidepressant; Atypical antipsychotic; Combination therapy; Major depressive disorder; Residual symptoms; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; ISOCARBOXAZID; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENELZINE; PINDOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE; ZIPRASIDONE;

ABSENCE OF SIDE EFFECTS; AKATHISIA; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; DELUSION; DOSE RESPONSE; HALF LIFE TIME; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INCREASED APPETITE; MAJOR DEPRESSION; REVIEW; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG SYNERGISM; DRUG THERAPY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 33745948393     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.7.1049     Document Type: Review

References (87)

1. WHO. The World Health Report 2001. Mental health: new understanding, new hope. WHO, Geneva, Switzerland (2001).
2. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder. Results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch. Gen. Psychiatry 62, 1097-1106 (2005).
3. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull. World Health Organ. 82, 858-866 (2004).
4. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Arch. Gen. Psychiatry 61, 1097-1103 (2004).
5. Sackeim HA. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry 62(Suppl. 16), 10-17 (2001).
6. Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J. Affect Disord. 89, 1-11 (2005). Review of antidepressant combinations in treatment-resistant depression.
7. Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry 163, 232-239 (2006).
8. Petersen TJ. Enhancing the efficacy of antidepressants with psychotherapy. J. Psychopharmacol. 20(Suppl. 3), 19-28 (2006).
9. Fava M. Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiatry 62(Suppl. 18), 4-11 (2001).
10. Young JP, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br. Med. J. 2, 1315-1317 (1979).
11. Razani J, White KL, White J et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch. Gen. Psychiatry 40, 657-661 (1983).
12. O'Brien S, McKeon P, O'Regan M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. Br. J. Psychiatry 162, 363-368 (1993).
13. Davidson J, McLeod M, Law-Yone B, Linnoila M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch. Gen. Psychiatry 35, 639-642 (1978).
14. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am. J. Psychiatry 151, 1372-1374 (1994).
15. Fava M, Alpert J, Nierenberg A et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J. Clin. Psychopharmacol. 22, 379-387 (2002).
16. Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol. Psychiatry 55, 296-300 (2004).
17. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19, 177-182 (1999).
18. Ferreri M, Lavergne FL, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression nonresponders to fluoxetine alone. Acta Psychiatr. Scand. 103, 66-72 (2001).
19. Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Bech P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the cute treatment of major depression. Pharmacopsychiatry 31, 48-54 (1998).
20. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomized study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology 161, 143-151 (2002).
21. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol. Psychiatry 51, 183-188 (2002).
22. Souery D, Amsterdam J, de Montigny C et al. Treatment resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol. 9, 83-91 (1999).
23. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28-40 (2006).
24. Thase ME. Effectiveness of antidepressants: comparative remission rates. J. Clin. Psychiatry 64(Suppl. 2), 3-7 (2003).
25. The UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361, 799-808 (2003).
26. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Nonresponse to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 128, 421-425 (1996).
27. Amsterdam JD, García-España F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress. Anxiety 5, 84-90 (1997).
28. Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J. Affect Disord. 34, 187-192 (1995).
29. König F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry 30, 93-96 (1997).
30. Hawley CJ, Quick SJ, Ratnam S, Pattinson HA, McPhee S. Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. Int. Clin. Psychopharmacol. 11, 187-191 (1996).
31. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J. Clin. Psychiatry 55, 24-25 (1994).
32. Levitt AJ, Joffe RT, Kamil R, McIntyre R. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? J. Clin. Psychiatry 60, 613-616 (1999).
33. Zajecka JM, Jeffries H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J. Clin. Psychiatry 56, 338-343 (1995).
34. Spier SA. Use of bupropion with SRIs and venlafaxine. Depress. Anxiety 7, 73-75 (1998).
35. Kennedy SH, McCann SM, Masellis M et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J. Clin. Psychiatry 63, 181-186 (2002).
36. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion SR augmentation of partial and nonresponders to serotonergic antidepressants. J. Clin. Psychopharmacol. 23, 27-30 (2003).
37. Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J. Clin. Psychiatry 65, 337-340 (2004).
38. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J. Clin. Psychiatry 60, 45-49 (1999)
39. Lucca A, Serretti A, Smeraldi E. Effect of reboxetine augmentation in SSRI resistant patients. Hum. Psychopharmacol. 15, 143-145 (2000).
40. Hawley CJ, Sivakumaaran T, Ochocki M, Bevan J. Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depression. 13th Congress of the European College of Neuropsychopharmacology, Munich, Germany S184 (2000).
41. Rubio G, San L, López-Muñoz F, García-García P, Álamo C. Combination therapy with reboxetine for major depression patients who are partial or nonresponders to serotonin selective reuptake inhibitors. Actas Esp. Psiquiatr. 31, 315-324 (2003).
42. Rubio G, San L, López-Muñoz F, Alamo C. Reboxetine adjunct for partial or nonresponders to antidepressant treatment. J. Affect Disord. 81, 67-72 (2004).
43. Tiller JWG, Mitchell P, Burrows GD. Monoamine oxidase inhibitors (MAOI) or reversible inhibitors of monoamine oxidase (RIMA)/tricyclic antidepressant (TCA) combination therapy. Aust. NZJ Psychiatry 26, 327-329 (1992).
44. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry 65, 62-67 (2004).
45. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J. Clin. Psychiatry 66, 844-848 (2005).
46. Dimellis D. Serotonin syndrome produced by a combination of venlafaxine and mirtazapine. World J. Biol. Psychiatry 3, 167 (2002).
47. Robertson MM, Trimble MR. Major tranquilizers used as antidepressants: a review. J. Affect Disord. 4, 173-193 (1982).
48. Ellis PM, Hickie IB, Smith DA. RANZCP Clinical Practice Guidelines. Summary of guideline for the treatment of depression. Australas Psychiatry 11, 34-38 (2003).
49. Kennedy S, Lam R, Cohen N, Ravindran A. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can. J. Psychiatry. 46(Suppl. 1), S38-S58 (2001).
50. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. National Institute for Clinical Excellence, London, UK (2004).
51. Schatzberg AF. New approaches to managing psychotic depression. J. Clin. Psychiatry 64(Suppl. 1), 19-23 (2003).
52. Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J. Clin. Psychiatry 60, 116-118 (1999).
53. Matthews JD, Bottonari KA, Polania LM et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J. Clin. Psychiatry 63, 1164-1170 (2002).
54. Anton RF, Burch EA. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am. J. Psychiatry 147, 1203-1208 (1990).
55. Mulsant BH, Sweet RA, Rosen J et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J. Clin. Psychiatry 62, 597-604 (2001).
56. Spiker DG, Cofsky Weiss J, Dealy RS et al. The pharmacological treatment of delusional depression. Am. J. Psychiatry 142, 430-436 (1985),
57. Rothschild AJ, Williamson DJ, Tohen MF et al. Double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J. Clin. Psychopharmacol. 24, 365-373 (2004).
58. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J. Clin. Psychiatry 66(Suppl. 8), 13-21 (2005).
59. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J. Clin. Psychiatry 65, 975-981 (2004).
60. Dubé S, Andersen SW, Paul SA et al. Meta-analysis of olanzapine-fluoxetine use in treatment-resistant depression [abstract]. Eur. Neuropsychopharmacol. 12(Suppl. 3), S180 (2002).
61. Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158, 131-134 (2001). Randomized controlled trial of olanzapine-fluoxetine combination versus olanzapine and fluoxetine monotherapies.
62. Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry 66, 1289-1297 (2005). Randomized controlled trial of olanzapine-fluoxetine combination compared with olanzapine, fluoxetine and nortriptyline monotherapies.
63. Benazzi F. Fluoxetine and olanzapine for resistant depression. Am. J. Psychiatry 159, 155-156 (2002).
64. Corya SA, Andersen SW, Detke HC et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J. Clin. Psychiatry 64, 1349-1356 (2003).
65. Parker G, Brotchie H, Parker K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? Am. J. Psychiatry 162, 796-798 (2005).
66. Devarajan S, Dursun SM. Olanzapine plus venlafaxine in treatment-resistant depression. J. Psychopharmacol. 19, 434-435 (2005).
67. Caetano D, Caetano SC. Olanzapine in the treatment of resistant depression. Aust. NZJ Psychiatry 39, 108-109 (2005).
68. Wang TS, Chou YH, Shiah IS. Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 306-309 (2006).
69. O'Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J. Clin. Psychopharmacol. 18, 89-91 (1998).
70. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry 60, 256-259 (1999).
71. Hirose S, Ashby CR. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J. Clin. Psychiatry 63, 733-736 (2002).
72. Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression. J. Clin. Psychopharmacol. 20, 495-496 (2000).
73. Viner MW, Chen Y, Bakshi I, Kamper P. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J. Clin. Psychopharmacol. 23, 104-106 (2003).
74. Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J. Clin. Psychiatry 65, 217-221 (2004).
75. Simon JS, Nemeroff CB. Aripiprazole augmentation for the treatment of partially responding and nonresponding patients with major depressive disorder. J. Clin. Psychiatry 66, 1216-1220 (2005).
76. Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J. Clin. Psychiatry 66, 1326-1330 (2005).
77. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry 16, 189-194 (2004).
78. Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J. Child Adolesc. Psychopharmacol. 15, 696-702 (2005).
79. McIntyre A, Gendron A, McIntyre A. Quetiapine reduces residual depressive and prominent anxiety symptoms in partial responders to selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) with major depression: an 8-week, double-blind, randomized, placebo-controlled study. Presented at the 14th European Congress of Psychiatry. 4th-8th March, Nice, France (2006).
80. Thase ME, Rush AJ. What role do atypical antipsychotic drugs have in treatment-resistant depression? J. Clin. Psychiatry 63, 95-103 (2002). Review of atypical antipsychotics in treatment-resistant depression.
81. Rush AJ, Fava M, Wisniewski SR et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Controlled Clin. Trials 25, 119-142 (2004). Prospective, randomized, multistep clinical trial of treatment algorithm for major depressive disorder, currently in progress.
82. Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 354, 1243-1252 (2006).
83. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Commonwealth of Australia, Canberra, Australia (1999).
84. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 61(Suppl. 6), 4-6 (2000).
85. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry 66(Suppl. 8), 30-40 (2005). Review of pharmacodynamics of atypical antipsychotics relevant to treatment-resistant depression.
86. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother. Psychosom. 75, 139-153 (2006). Review of augmentation and combination treatment strategies in major depressive disorder.
87. Fava GA, Ruini C, Rafanelli C. Sequential treatment of mood and anxiety disorders. J. Clin. Psychiatry 66, 1392-1400 (2005).